ArticleDermatology research and practice2011
Molecular nevogenesis.
Article in Dermatology research and practice, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 60 citations in OpenAlex.
- Review: The Key Factors to Melanomagenesis.Life (Basel, Switzerland) · 2023Review
- New Insights into Melanoma Tumor Syndromes.JID innovations : skin science from molecules to population health · 2022Review
- The Morpho-Molecular Landscape of Spitz Neoplasms.International journal of molecular sciences · 2022Review
- A six-attribute classification of genetic mosaicism.Genetics in medicine : official journal of the American College of Medical Genetics · 2020Review
- A case of eruptive melanocytic nevi in an 8-year-old healthy boy.JAAD case reports · 2020Article
- Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications.Frontiers in molecular biosciences · 2020Review
- Malignant Transformation of a Multi-Operated Divided Nevus of the Eyelids.Ocular oncology and pathology · 2018Article
- Treatment of melanoma with selected inhibitors of signaling kinases effectively reduces proliferation and induces expression of cell cycle inhibitors.Medical oncology (Northwood, London, England) · 2017Article
- Ultraviolet radiation accelerates NRas-mutant melanomagenesis: A cooperative effect blocked by sunscreen.Pigment cell & melanoma research · 2017Article
- Treatment ofTherapeutic advances in medical oncology · 2017Review
- Surgical suturing-induced melanocytic nevi. A new type of eruptive melanocytic nevi?Journal of dermatological case reports · 2016Article
- Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.Pathology · 2016Review
- Conceptual approach to early melanoma detection: models, tools, issues and challenges.Melanoma management · 2015Review
- Genetics of melanocytic nevi.Pigment cell & melanoma research · 2015Review
- Mutational status of naevus-associated melanomas.The British journal of dermatology · 2015Article
- NRAS-mutated melanocytic BAP1-associated intradermal tumor (MBAIT): a case report.Virchows Archiv : an international journal of pathology · 2015Article
- Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis.Acta neuropathologica communications · 2014Article
- No one should die of melanoma: a vision or impossible mission?Melanoma management · 2014Review
- NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.The Journal of investigative dermatology · 2014Article
- Controversial aspects of oncogene-induced senescence.Cell cycle (Georgetown, Tex.) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent advances, the biology underlying nevogenesis remains unclear. Activating mutations in NRAS, HRAS, BRAF, and GNAQ have been identified in benign nevi. Their presence roughly correlates with congenital, Spitz, acquired, and blue nevi, respectively. These mutations are likely to play a critical role in driving nevogenesis. While each mutation is able to activate the MAP kinase pathway, they also interact with a host of different proteins in other pathways. The different melanocytic developmental pathways activated by each mutation cause the cells to migrate, proliferate, and differentiate to different extents within the skin. This causes each mutation to give rise to a characteristic growth pattern. The exact location and differentiation state of the cell of origin for benign moles remains to be discovered. Further research is necessary to fully understand nevus development given that most of the same developmental pathways are also present in melanoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.